Interview with our CEO at bionity.com
Nutrient media for the development of regenerative therapies
In the latest interview at bionity.com, our CEO Dr. Hatim Hemeda talked about the history and background idea of PL BioScience to develop nutrient media for the development of regenerative therapies.
As a young life science company we develop, produce and distribute Human Platelet Lysate (HPL) as a cell culture medium. The goal is to create an animal-free and qualitatively superior alternative to the market standard, which is based on blood from fetal calves (FBS).
Read more about PL BioScienceBionity.com is a leading portal for life sciences and pharmaceuticals
At the platform bionity.com users from the life science and pharmaceutical industry, research and science find the latest news and events in these markets. The user of bionity.com can choose between four languages and read about trends and technology in laboratories, bioprocesses or production. Additionally, bionity.com reports about offers for further education, specialties and knowledge of a product and business interview with experts.
Read more about Bionity.com here
Challenges to solve and visions to chase
When founding and building up a company there are of course challenges to face but also visions to face and successes to celebrate. One of these challenging but also rewarding times for our CEO was the starting times of PL BioScience:
“We have grown organically, with everything that goes with it in the first few years: Long working days with many cups of coffee, a small team that lends a hand in all areas and values the hands-on mentality. It was an exciting time with many development processes. Our perseverance and team spirit was rewarded: Recently, we were able to win well-known investors who support us with financial resources and their industry know-how. It is an indescribable feeling that not only our customers and partners but also investors with industry experience are supporting us on our mission. We were able to expand our team and we succeeded in bundling our broad HPL portfolio into the platform technology ELAREM™, which we are constantly developing with a view to market requirements.” (source: https://www.bionity.com/de/news/1175523/naehrmedium-fuer-die-entwicklung-regenerativer-therapien.html)
From the idea of commercial Human Platelet Lysate to a company
Furthermore, Dr. Hemeda gives an inside into the founding process with his business partner and friend Christian Wilkes. From the idea of an ethical and standardized cell culture medium that can replace the current “Gold Standard” (Fetal Bovine Serum) – to the first steps of an own company and hiring of a highly motivated interdisciplinary team.
Read the interesting answers to the questions on bionity.com:
- How was your development process? What were the biggest challenges and setbacks?
- What was the reaction of the market and industry?
- Would you go this route again – or is there something you would do differently?
- What can others learn from your start-up story?
Read the whole German interview
